BRIEF-Innovent Announces Strategic Collaboration With Lilly To Develop New Medicines Globally In Oncology And Immunology

Eli Lilly and Company -1.89% Post

Eli Lilly and Company

LLY

905.03

905.27

-1.89%

+0.03% Post

- Innovent Biologics Inc 1801.HK:

  • INNOVENT ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY

  • INNOVENT BIOLOGICS - INNOVENT WILL RECEIVE A $350 MILLION UPFRONT PAYMENT

  • INNOVENT BIOLOGICS: IS ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY & COMMERCIAL MILESTONE PAYMENTS UP TO EST $8.5 BILLION CONTINGEN CERTAIN FUTURE EVENTS

  • : INNOVENT ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY

Source text: ID:nPn5mzt1ta

Further company coverage: [1801.HK LLY.N]